Effective July 29, 2015


BioCure is pleased to announce that we are now dispensing XELJANZ (tofacitinib citrate) for the treatment of moderate to severe Rheumatoid Arthritis.


XELJANZ may be used as monotherapy or in combination with methotrexate or other non- biologic disease-modifying anti-rheumatic drugs (DMARDs).


The recommended dose of XELJANZ is one 5 mg Tablet twice daily.


Related Links to post: http://www.xeljanz.com/